Cullinan Therapeutics, Inc. (CGEM)
(Real Time Quote from BATS)
$20.13 USD
+0.22 (1.11%)
Updated Jul 26, 2024 10:28 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Cullinan Therapeutics (CGEM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$33.67 | $40.00 | $28.00 | 69.11% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Cullinan Therapeutics comes to $33.67. The forecasts range from a low of $28.00 to a high of $40.00. The average price target represents an increase of 69.11% from the last closing price of $19.91.
Analyst Price Targets (6 )
Broker Rating
Cullinan Therapeutics currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, eight are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/3/2024 | H.C. Wainwright & Co. | Edward White | Strong Buy | Strong Buy |
5/16/2024 | Wedbush Securities | Robert Driscoll | Strong Buy | Strong Buy |
5/16/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/15/2024 | SVB Securities | Andrew Berens | Strong Buy | Strong Buy |
4/17/2024 | BTIG | Kaveri Pohlman | Strong Buy | Strong Buy |
4/15/2024 | William Blair | Matt Phipps | Not Available | Strong Buy |
4/1/2024 | Cowen & Co. | Marc Frahm | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 8 |
Average Target Price | $33.67 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 252 |
Current Quarter EPS Est: | -0.73 |